相关临床试验
97
7 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1878
进行中（未招募）
2
2.1%
已完成
59
60.8%
Enrolling By Invitation
1
1.0%
尚未招募
4
4.1%
招募中
7
7.2%
终止
5
5.2%
Unknown
16
16.5%
撤回
3
3.1%
暂无批准数据
- Researchers at Université de Montréal and IRCM discovered that SLAMF6 acts as an internal, self-activating immune checkpoint on T cells that operates independently of tumor signals, explaining why many cancers resist PD-1/PD-L1 inhibitors. - Unlike PD-1 or CTLA-4, SLAMF6 binds to itself on the T cell surface, suppressing progenitor exhausted T cells and accelerating immune exhaustion without requiring any signal from the tumor microenvironment. - Custom monoclonal antibodies developed by the team blocked SLAMF6 self-binding, increasing T cell activation, boosting durable immune cell populations, and producing strong anti-tumor responses in mouse models. - The findings, published in Nature, open a new class of cancer immunotherapies potentially applicable to the 40–50% of solid tumors that respond poorly to existing checkpoint inhibitors, with human clinical trials expected in 3–5 years.
- Researchers at Université de Montréal have identified SLAMF6 as a novel immune checkpoint molecule that functions autonomously on T cell surfaces to suppress anti-tumor immunity. - Unlike PD-1 and CTLA-4, SLAMF6 operates through cis homotypic interactions on T cells themselves, accelerating T cell exhaustion independently of tumor cell interactions. - Monoclonal antibodies targeting SLAMF6 demonstrated enhanced T cell activation and tumor growth suppression in preclinical models, offering potential for patients resistant to current checkpoint inhibitors. - The discovery represents a paradigm shift toward addressing intrinsic immune regulatory checkpoints and may enable combination therapies that surpass current immunotherapy limitations.
- Ipsen has expanded its five-year collaboration with Université de Montréal and IRICoR by adding two new discovery-stage oncology programs targeting pathways complementary to the MAP kinase pathway. - The partnership expansion marks the second time the collaboration has grown since its 2020 establishment, bringing the total number of active research programs to four. - IRICoR will advance compounds to drug candidate stage, after which Ipsen may exercise options to assume global development, manufacturing, and commercialization responsibilities. - The collaboration has already produced IPN01195, an investigational RAF inhibitor currently in Phase I clinical trials, demonstrating the partnership's potential for clinical translation.
- The phase 3 BURAN trial demonstrated that buparlisib plus paclitaxel did not improve overall survival compared to paclitaxel alone in patients with PD-1/PD-L1-pretreated recurrent/metastatic head and neck squamous cell carcinoma, with median survival times of 9.6 versus 9.7 months respectively. - Despite showing a numerically higher overall response rate (30.3% vs 20.7%), the combination therapy was associated with significantly more severe adverse events, with 87.5% of patients experiencing grade 3 or higher side effects compared to 59.4% in the paclitaxel-alone group. - The study enrolled 487 patients between April 2021 and November 2023, highlighting the continued unmet medical need in immunotherapy-refractory head and neck cancer patients. - Subgroup analysis suggested potential survival benefit in HPV-positive oropharynx cancer patients and North American patients, though these findings require further investigation through translational studies.
- Researchers at Université de Montréal developed a DNA-based electrochemical sensor that detects drug concentrations from a single drop of blood within five minutes. - The technology uses engineered DNA aptamers that bind to drug molecules and trigger electrochemical signals, mimicking natural cellular signaling cascades. - The sensor demonstrated exceptional sensitivity, detecting molecules at concentrations up to 100,000 times lower than glucose levels. - Montreal-based startup Anasens has licensed the patent for commercialization, potentially transforming therapeutic drug monitoring into a point-of-care procedure.
- Epitopea's CryptoMap platform identified 589 non-redundant tumor antigens in cutaneous melanoma and NSCLC, with only 1% derived from mutated sequences. - The platform discovered that 37% of identified tumor antigens were Cryptigens, which are immunogenic, shared among tumor samples, and could contribute to immune checkpoint blockade responses. - This research challenges the conventional focus on mutated tumor antigens and validates unmutated sequences as actionable targets for cancer immunotherapy. - The findings distinguish Epitopea's approach from other immunotherapy companies and support the development of accessible off-the-shelf RNA-based immunotherapies.
- Recent research reveals specific bacterial networks in the gut microbiome can predict cancer patients' response to immunotherapy, with Akkermansia muciniphila and Faecalibacterium prausnitzii identified as beneficial species. - Broad-spectrum antibiotics significantly reduce survival rates in cancer patients undergoing immunotherapy, with a meta-analysis of 46,000 patients showing a 1.7-fold higher risk of reduced survival. - Novel interventions, including a specialized charcoal capsule and fecal microbiota transplantation, show promising results in preserving microbiome diversity and enhancing immunotherapy effectiveness in clinical trials.
